Article Text
Statistics from Altmetric.com
- hydroxychloroquine
- lupus erythematosus, systemic
- epidemiology
- communicable diseases, imported
- autoimmune diseases
In vitro inhibition of the novel coronavirus, SARS-CoV-2, by hydroxychloroquine (HCQ) has triggered further exploration of the clinical efficacy of this drug in covid-19. Rheumatologists all over the world are analysing registries of patients with systemic lupus erythematosus (SLE) and other rheumatic diseases to look at the prevalence of covid-19 in patients who have been on HCQ. On coming across the title, ‘SLE, hydroxychloroquine and no SLE patients with covid-19: a comment’, we read it with interest. The authors say, “There are several thousands of patients with covid-19 worldwide. Nevertheless, there is no case of SLE with covid-19”. There is no mention of any reference or source to the claim. They go on to extrapolate, “Hence, hydroxychloroquine …
Footnotes
Twitter @drmohitgoyal
Contributors MG prepared the manuscript and approved for final submission.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; internally peer reviewed.